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Abstract
Purpose. Patients with metabolic syndrome (MetS) have potentially higher risk for cardiovascular 
events. The aim of this study was to evaluate the effect  of MetS on cardiac events in type-2 diabetic 
patients asymptomatic for coronary artery disease (CAD) in a Japanese population.
Methods. A total of 485 patients from a J-ACCESS-2 investigation with stress gated myocardial 
perfusion imaging (MPI) and quantitative gated MPI analysis (QGS) were examined. 
Cardiovascular hard events (cardiac death and acute coronary syndrome) and total events during a 
three-year follow-up were analyzed.
Results . The MetS group  (n=229) had higher incidence of hypertension, dyslipidemia and 
ventricular dilatation than the non-MetS group (n=256). The hard events were 8 and 12 for the 
MetS and non-MetS groups (p=n. s.), and total events were 31 and 31 for each of these groups, 
respectively (p=n. s.). Significant variables related to total cardiovascular events included age, 
current smoking, insulin use, total cholesterol, ejection fration, summed stress score ≥9 and 
summed difference score ≥2. Cox proportional hazard analysis and Kaplan-Meier survival analysis 
showed that only the summed stress score was related to total events (p=0.01), and the presence and 
number of items for MetS criteria were not.
Conclusion. In patients with type-2 diabetes asymptomatic for CAD, cardiovascular events and 
ischemia are as common in diabetic patients without MetS as in those with MetS. A high MPI 
defect score is related to total events including cardiac and cerebrovascular events.
Key words: metabolic syndrome, type-2 diabetes, myocardial perfusion imaging, multi-center 
study, prognosis
Introduction
 Metabolic syndrome (MetS) is defined by 
the combina t ions o f d iabe tes me l l i tus , 
hypertension, dyslipidemia, central obesity and 
microa lbuminur ia by the Wor ld Hea l th 
Organization and National Cholesterol Education 
Program Adult Treatment Panel III, and it  is 
considered an important risk factor for future 
cardiovascular events [1, 2]. The Japanese Society 
for the Study of Obesity also used the MetS criteria 
of abdominal circumference, blood pressure 
(130/85), triglyceride (150 mg/dL) or HDL 
cholesterol <40 mg/dL and blood glucose (≥110 
mg/dL). In this metabolic status, cardiovascular 
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event  risk has been demonstrated to be higher with 
a hazard ratio of 1.70-1.86 in a general Japanese 
population [3, 4]. Diabetes and CKD were both 
significant risk factors for cardiovascular events in 
Japanese prognostic cohort study (J-ACCESS 
study) using myocardial perfusion imaging (MPI) 
[5, 6].
 Subsequently, a J-ACCESS-2 study has 
been performed in Japan in patients with diabetes 
asymptomatic for coronary artery disease (CAD) 
[7, 8]. There have been no studies in Japan dealing 
with asymptomatic patients with MetS and its 
relationship to cardiovascular events in conjunction 
with MPI. Our hypothesis in this study was that 
MetS might increase the risk of cardiovascular 
events even in patients with diabetes asymptomatic 
for CAD. The significance of perfusion 
abnormality in this study group was also examined.
Methods
Subjects
 J-ACCESS-2 prognost ic databases 
involving 513 patients from 50 institutions were 
used with a follow-up period of 3 years [7]. The 
criteria for registry included patients with type 2 
diabetes, ≥50 years of age, who either had maximal 
carotid artery intima-media thickness ≥1.1 mm by 
ultrasonography or a urinary albumin excretion rate 
of ≥30 mg/g creatinine, or patients who satisfied at 
least two of the following four conditions: 
abdominal obesity with body mass index (BMI) 
≥25 and waist circumference ≥85 cm for men and 
≥90 cm for women, hypo-high density lipoprotein 
( H D L ) - c h o l e s t e r o l e m i a ( < 4 0 m g / d l ) , 
hyper t r ig lycer idemia (≥150 mg/dl ) , and 
hypertension (blood pressure ≥130/ 85 mmHg). 
Exclusion criteria included patients with 
myocardial infarction, effort  angina, unstable 
a n g i n a , a n d t h o s e w i t h a b n o r m a l 
electrocardiographic findings of ST  depression 
>1mm, mult i focal premature ventr icular 
contraction, tachyarrhythmia and atrial fibrillation. 
Also excluded were patients with hemoglobin A1c 
(HbA1c) ≥10% or serum creatinine ≥1.5 mg/dl, 
valvular heart  disease, idiopathic cardiomyopathy, 
New York Heart Association class III or IV heart 
failure at the time of MPI, and arteriosclerosis 
obliterans of the lower extremities (with 
intermittent claudication, resting pain and 
ulceration). 
 An institutional review board or committee 
approved the study in all institutions, and written 
informed consent was obtained from all subjects.
Definition of metabolic syndrome
 In this subanalysis of the J-ACCESS-2 
investigation, the criteria of MetS were determined 
by three or more of the following conditions: (1) 
BMI ≥25 kg/m2, (2) dyslipidemia (triglyceride 
≥150 mg/dL, HDL cholesterol ≤40 mg/dL, or 
medication for dyslipidemia), (2) hypertension 
(systolic pressure ≥130 mmHg, diastolic pressure 
≥85 mmHg or medication for hypertension) and (3) 
diabetes (fasting blood sugar≥110 mg/dL, or 
medications or insulin therapy for diabetes). 
Abdominal circumference criteria were not used in 
this subanalysis [9].
Myocardial perfusion imaging
 Stress-rest  MPI was performed with 99mTc-
tetrofosmin. Exercise (71%) or pharmacological 
stress (29%) with dipyridamole, adenosine or 
adenosine triphosphate was performed. The 
average dose of 99mTc-tetrofosmin administered 
was 331 MBq for the initial study and 748 MBq for 
the second study. MPI data acquisition was 
performed with standard protocols, and a gated 
study was performed at least  at resting condition. 
Myocardial images of short-axis, vertical long-axis 
and horizontal long-axis images were generated 
and interpreted using a 20-segment model. 
Segmental myocardial defects were visually scored 
using a 5-point scoring system: 0 = normal, 1 = 
mildly reduced, 2 = moderately reduced, 3 = 
severely reduced, and 4 = absent. Total defect 
scores were calculated as the sum of stress, rest  and 
difference scores (SSS, SRS, and SDS). Four SSS 
severity categories were used for risk-based groups 
of 0–3 (normal), 4–8 (mild), 9–13 (moderate), and 
≥14 (severe). Quantification of the gated SPECT 
was performed by QGS software (Cedars Sinai 
Medical Center, Los Angeles, CA, USA) at  each 
institution. The left ventricular ejection fraction 
(LVEF, %), end-diastolic volume (EDV, ml), and 
end- systolic volume (ESV, ml) were calculated.
 Coronary angiography was performed in 48 
patients after MPI, and significant  coronary artery 
stenosis was observed in 11 patients with MetS and 
14 with non-MetS. The multi-vessel disease was 
observed in 4 patients with MetS and 8 with non-
MetS (p=0.93 for number of coronary artery 
stenosis between MetS and non-MetS groups).
Definition of events and follow-up
 The cardiovascular and cerebrovascular 
events were investigated each year after the 
registration. After excluding patients who had early 
revascularization within 30 days after registration 
(n=7), noncardiac death (n=7) and patients lost 
during follow-up (n=14), a total of 485 patients 
were selected for prognostic analysis. Events of 
cardiac death, sudden death (natural, rapid and 
unexpected death from cardiac causes: witnessed 
cardiac arrest or death <1 hour after the onset, or 
unwitnessed deaths within 24 hours after the 
patients were last  seen to be alive), and nonfatal 
acute coronary syndrome (ACS) were defined as 
hard events. Total cardiovascular events further 
included percutaneous coronary intervention (PCI), 
- 2 -
coronary artery bypass grafting (CABG), de novo 
diagnosed stable angina, unstable angina and 
severe heart failure requiring hospitalization. Other 
vascular-related events such as transient  ischemic 
attack of the brain, stroke, and de novo diagnosed 
peripheral vascular disease with intermittent 
claudication, resting pain and ulceration were also 
included in the total events.
Statistics
 Continuous variables are expressed as 
mean ± standard deviation (SD). We applied the 
Wilcoxon rank sum test  to compare results from 
patients with and without  cardiovascular events and 
the Chi-square test  to categorical data. The 
univariate Cox proportional hazard model was used 
to evaluate each variable. The dependent  variable 
included the occurrence of total events, 
cardiovascular events and death. The relative 
hazard ratios (HRs) and 95% confidence of interval 
(CI) were calculated. The multivariate Cox 
proportional model was applied based on 
statistically significant  independent variables. 
Kaplan-Meier analysis was also peformed to 
analyse survival curves. Statistical significance was 
defined as p<0.05.
Results
Comparison of groups between MetS and non-
MetS groups
 Based on the definition of MetS, 229 
patients were classified into the MetS group and 
256 into the non-MetS group (Table 1). The MetS 
group showed higher BMI and larger abdominal 
circumference than the non-MetS group. With 
respect to dyslipidemia, HDL cholesterol was lower 
in the MetS group, but low-density lipoprotein 
(LDL) cholesterol was comparable between both 
groups. Gated SPECT showed that  EDV and ESV 
were higher in the MetS group than in the non-
MetS group. However, the degree of ischemia as 
determined by SSS or SDS and resting perfusion 
defect  by SRS was similar between MetS ans non-
MetS groups. During the follow up of three years, 
14 cardiovascular hard events occurred. The event 
rate of cardiac death and cardiovascular events did 
not differ significantly between the two groups. 
When the breakdown of total events other than 
death was observed, cardiac disease related events 
totaled 11 for MetS and 19 for non-MetS groups, 
cerebrovascular events numbered 15 for MetS and 
6 for non-MetS groups, and peripheral vascular 
disease related events totaled 3 for MetS and 3 for 
non-MetS groups (Pearson test, p=0.103).
Cox proportional hazard analysis
 Based on univariate Cox proportional 
hazard analysis, significant  variables related to total 
events included age, current  smoking, insulin use, 
total cholesterol, LVEF, SSS ≥9 and SDS ≥2 (Table 
2). However, to predict  cardiovascular hard events, 
only insulin and urea nitrogen were significant, and 
SSS, SDS and eGFR were not  significant. In the 
hard events, the multivariate analysis was not 
accepted because of a relatively low incidence of 
hard events. In the total events, multivariate 
analysis showed no additional variables to the 
SSS≥9. Coronary arter stenosis documented during 
the course of follow-up was analyzed by the 
univariate analysis. The hazard ratios of the 
presence of coronary artery stenosis for total events 
were 4.63 (p<0.0001), and that  for cardiovascular 
hard events was 3.57 (p=0.096).
MetS as a predictor of events
 To evaluate the role of variables related to 
MetS, the presence of MetS and the number of 
items for MetS were included for Cox proportional 
hazard analysis (Table 3). However, the variables 
of MetS were not significantly related to cardiac 
death and total events. In contrast, SSS ≥9 and 
SDS≥2 were significantly related to total events 
(HR= 2.32 for SSS and 3.45 for SDS). 
Differences in medication
 When the MetS and non-MetS groups were 
compared, the MetS group had higher incidences of 
biguanide (23.1% vs. 14.1%, p<0.0138), 
angiotensin II antagonist  (45.1% vs. 30.1%, 
0.0010), calcium channel blocker (53.7% vs. 
32.8%, p<0.0001), alfa blocker (8.3% vs. 2.3%, 
p=0.0059), and lower incidence of aspirin (15.7% 
vs. 25.8%, p=0.0093). No statistical differences 
were found between the two groups in terms of 
medication of sulfonyluria (47.2% vs. 43.0%, 
p=0.40), statin (38.4% vs. 31.6%, p=0.14) and 
insulin use (27.1% vs. 32.4%, p=0.24).
Survival analysis
 Kaplan-Meier survival analysis was 
performed in patients with SSS ≤9 and <9, and with 
and without  MetS (Figure 1). When all events were 
analyzed, the SSS ≥9 group showed higher 
incidence of total events, but  cardiovascular events 
including cardiac death, sudden death and ACS did 
not reach statistical significance when both groups 
were compared. Patients with and without MetS did 
not show significant differences in total event 
analysis. When patients were classified based on 
SSS and MetS, the groups differed significantly. 
However the contribution of SSS was more 
significant as shown in Figure 1D.
Discussion
 MetS is an important predictor of 
cardiovascular events. In asymptomatic patients 
with diabetes, however, the effects of additional 
factors of MetS on cardiovascular events have not 
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been clarified. In this subanalysis based on J-
ACCESS-2 databases, we classified patients into 
MetS and non-MetS groups and found that  the only 
factor related to total cardiovascular events was 
myocardial perfusion abnormality at stress or 
ischemia, and the MetS was not  the significant 
predictor in this study population. Cardiovascular 
events and ischemia were commonly observed in 
diabetic patients without MetS as in the case in 
those with MetS.
 The J-ACCESS-2 investigation was a 
multicenter prognostic investigation involving 
asymptomatic type-2 diabetes [8]. The selection 
criteria included abdominal circumference, BMI, 
hypertension and dyslipidemia. The MetS criteria 
were satisfied in approximately half of the 
asymptomatic patients. The total event rate was 
observed in 13% of the patients, although the 
cardiac death rate was relatively small. Multivariate 
Cox proportional hazard analysis showed that 
significant variables for total cardiovascular events 
comprised stress perfusion defect  (SSS ≥9), a low 
eGFR, and being a current smoker. We therefore 
tried to clarify the contribution of MetS to 
occurrence of cardiovascular events, since a non-
invasive stress test was sometimes indicated even 
in asymptomatic populations of MetS. However, 
although the MetS group showed a higher 
incidence of abnormalities for dyslipidemia, 
hypertension and eGFR as well as large ventricular 
volumes than the non-MetS group, no difference 
was observed between the two groups with respect 
to total and hard cardiovascular event rates. 
 There was no difference in any of the MPI 
variables between the MetS and no Mets groups. 
This was probably caused by the therapeutic effects 
for ischemia including PCI and medication, which 
resulted in reduction of hard cardiovascular events. 
It  should be noted that  abnormality of MPI was 
related to total events including cerebrovascular 
events and peripheral vascular events. MPI 
abnormality cannot directly be used as a predictor 
for non-cardiac events. However, cerebrovascular 
events are the third highest  cause of mortality in 
Japan, and factors of diabetes, dyslipidemia and 
hypertension, in addition to an aging society, are 
major backgrounds commonly found related to the 
total events in this study. Considering these 
metabolic factors, the higher total event rate in 
patients with abnormal MPI might be explained.
 A study in the United States using 7,849 
patients from a multicenter prospective registry 
analyzed the importance of MetS for predicting 
cardiovascular events [10]. There was an additive 
value in predicting major cardiac events using the 
number of risk factors for MetS and the extent and 
severity of abnormalities in MPI. Patients with five 
risk factors of MetS were of particularly high risk 
showing hazard ratios from 7.8 to 14.1-fold for 
mild to severely abnormal MPI findings. Acampa et 
al. showed that in a IDIS multicenter prospective 
study in diabetec patients, addition of MPI data to a 
prediction model based on traditional risk factors 
and ECG stress test data significantly improved 
coronary heart  disease risk classification [11]. In a 
Japanese study involving 1,424 type-2 diabetic 
patients, a high prevalence (38-53%, depending on 
sex and definition) of MetS was found among 
diabetic patients [12]. Although coronary heart 
disease events were observed in 4.4% during an 8-
year study, the individual components of MetS, 
such as hyperlipidemia or hypertension, were 
equivalent  or better predictors than the definition of 
MetS in men. The present study did not  confirm the 
significance of MetS for major cardiovascular 
events. This was probably due to selection bias 
during the J-ACCESS-2 investigation, since cardiac 
death and cardiovascular hard event  rates were in 
1.2% and 2.9% per 3 years, respectively. Another 
factor for contributing to the equivalent event rate 
was the effect of more active medications in the 
MetS group, which presumably improved their 
metabolic status and reduced mortality. Therefore, 
in the group with a low-risk profile for coronary 
artery disease and medically treated patients as in 
the J-ACCESS-2 study, MetS was not the major 
predictor of cardiac events.
 This subanalysis was performed to see 
whether the presence of MetS had siginifcant 
effects on screening in patients with type 2 
diabetes. The effectiveness of screening by MPI in 
asymptomatic diabetic patients was investigated in 
a DIAD-2 study [13]. It was found that cardiac 
event  rates were low and were not significantly 
reduced by MPI screening for myocardial ischemia 
over a 4.8 year period. However, the positive 
predictive value of having moderate or large MPI 
defects was 12%. Although screening all patients 
with diabetes is not justified, restricting screening 
to a patient  population in which a relatively high 
positive yield can be ensured would be a practical 
approach. [14, 15]. In fact the factor of SSS≥9 
showed high total event  rate in this study. Based on 
the MPI stress abnormality, optimal medical 
therapy and/or percutaneous coronary intervention 
would be indicated for those patients, which might 
subsequently result  in improved patient outcome. 
The selection criteria for further non-invasive stress 
testing might include typical chest  symptoms, 
electrocardiographic abnormalities with treadmill 
exercise, high coronary calcium scoring, etc. as 
evidenced by nuclear cardiology guidelines in the 
USA and Japan [16, 17]. Coronary artery calcium 
scoring was not included in this study. Some of the 
patients with minimal or absent coronary 
calcification might have been excluded, and those 
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with increased atherosclerotic burden would have 
been indicated for MPI studies [18]. Since the 
impact  of MPI and MetS may also differ among 
ethnic backgrounds, an optimal test in symptomatic 
and non-symptomatic patients for CAD should be 
further investigated in various populations.
 Limitations. A larger number of subjects or 
a longer follow-up period are required to better 
analyze the hard cardiac events. Since only 
asymptomatic patients were included in this study, 
a comparative risk group study may be indicated by 
including symptomatic patients or those with 
moderate likelihood of coronary artery disease. The 
selection criteria for MetS used BMI≥25, which 
was lower than the criteria of WHO using ≥30, but 
it  has been noted that Japanese patients with type 2 
diabetes are not obese compared with American 
and some European poulations [19]. Although 
patients with type-1 diabetes appear to have greater 
risk of cardiac death than other patients based on 
any MPI result, we included type-2 diabetes in this 
study [20].
Conclusion
 In pa t ien ts wi th type 2 d iabe tes 
asymptomatic for CAD, the presence of MetS did 
not increase the rate of hard and total cardiac 
events. Cardiovascular events are observed in 
diabetic patients without MetS similar to those with 
MetS. However, moderate to severe SSS ≥9 
showed high incidence of total cardiovascular 
events. Therefore, a routine screening test by MPI 
for asymptomatic patients having MetS criteria is 
not indicated, but potentially higher-risk population 
should be further investigated.
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Table 1. Comparison of patient characteristics between MetS and non-MetS groups
MetS (n=229) Non-MetS (n=256) p
Age (years) 67±7 67±7 0.23
Male gender (%) 53% 62% 0.07
Body mass index (kg/m2) 27.7±2.7 22.1±1.9 <.0001
Abdominal circumference (cm) 92.5±10.2 81.2±7.6 <.0001
Max IMT (mm) 1.53±0.69 1.73±0.87 0.06
Hypertension 90.8% 75.8% <.0001
Dyslipidemia 84.7% 75.4% 0.02
  HDL cholesterol (mg/dL) 48.7±13.4 53.1±15.5 0.01
  LDL cholesterol (mg/dL) 120.0±29.4 115.2±32.6 0.12
  Triglyceride (mg/dL) 184.0±97.5 154.8±127.1 <.0001
Insulin 27.1% 32.4% 0.24
Statin 34.4% 31.6% 0.14
Creatinine (mg/dL) 0.81±0.25 0.77±0.23 0.06
eGFR (ml/min/1.73m2) 70.4±20.5 74.9±19.4 0.02
Urea Nitrogen (mg/dL) 17.1±5.1 16.6±5.0 0.33
Urinary albumin (log) 3.97±1.44 3.93±1.40 0.94
Gated SPECT analysis (QGS)
  EDV (mL) 77.1±23.0 70.5±20.7 0.003
  ESV (mL) 26.8±13.9 23.7±12.2 0.01
  EF (%) 66.7±9.6 67.9±9.9 0.38
Summed score by MPI
  SSS 2.92±4.64 2.77±4.55 0.29
  SRS 2.03±3.65 2.23±3.77 0.89
  SDS 0.88±3.25 0.54±2.33 0.65
Cardiovascular events
  Death 2 (0.9%) 3 (1.2%) 0.78
  Cardiovascular hard events 6 (2.6%) 8 (3.1%) 0.95
  Total events 31 (13.5%) 31 (12.1%) 0.74
IMT, intima-media thickness; MPI, myocardial perfusion imaging; EDV, end-diastolic volume; 
ESV, endsystolic volume; EF, ejection fraction; SSS, summed stress score; SRS, summed rest score; 
SDS, summed difference score
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Variables Wald χ2 Hazard 
Ratio
p Wald χ2 Hazard 
Ratio
p
Age 4.66 1.04 0.03 1.40 1.04 0.24
Sex 0.004 0.98 0.95 0.25 0.76 0.62
Body mass index 1.25 0.96 0.26 3.64 0.85 0.06
Family history of CAD 0.03 0.90 0.86 0.0001 0.00 0.99
Current smoking 4.29 1.85 0.04 0.01 1.10 0.91
Hypertension 3.59 2.42 0.06 0.21 0.75 0.65
Dyslipidemia 0.28 0.85 0.60 0.01 0.92 0.90
Insulin use 5.03 1.78 0.03 4.66 3.21 0.03
Medication of statin 3.54 0.57 0.06 2.36 0.31 0.12
ECG abnormality at rest 3.03 1.68 0.08 1.19 1.95 0.28
Total cholesterol 4.17 1.01 0.04 0.52 1.01 0.47
LDL-cholesterol 2.05 1.01 0.15 1.10 1.01 0.30
HDL-cholesterol 0.07 1.00 0.79 0.01 1.00 0.92
Triglyceride 0.23 1.00 0.63 0.53 1.00 0.47
Fasting blood sugar 3.56 1.00 0.06 3.78 1.01 0.05
Hemoglobin A1C (%) 1.41 0.88 0.23 0.03 0.96 0.85
Urea nitrogen 9.18 1.06 0.002 4.28 1.09 0.04
Creatinine 2.12 2.11 0.14 1.19 3.33 0.27
Urinary microalbumin 0.39 1.00 0.53 0.10 1.00 0.75
LVEF 5.13 0.97 0.02 2.10 0.96 0.15
EDV 0.001 1.00 0.97 0.24 0.99 0.63
ESV 1.25 1.01 0.26 0.12 1.01 0.73
SSS 2.51 1.04 0.11 0.71 1.04 0.40
SRS 0.39 1.02 0.53 0.89 1.05 0.34
SDS 3.21 1.06 0.07 0.01 1.01 0.90
Abdominal circumference 0.02 1.00 0.89 0.01 1.00 0.92
MaxIMT 0.00 1.01 0.97 0.04 1.14 0.84
eGFR 2.34 0.99 0.13 0.67 0.99 0.41
CAD, coronary artery disease; ECG, electrocardiogrm; EDV, end-diastolic volume; ESV, 
endsystolic volume; EF, ejection fraction; SSS, summed stress score; SRS, summed rest score; 
SDS, summed difference score; IMT, intima-media thickness;
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Table 3 Univariate Cox analysis for selected variables








 Criteria of MetS 0.17 1.11 0.67 1.82 0.68
 Number of items for MetS 0.33 1.16 0.70 1.93 0.56
 eGFR≥60, <60 1.56 1.42 0.82 2.45 0.21
 SSS?≥9, <9 6.42 2.32 1.21 4.46 0.011
 SDS?≥2, <2 5.73 3.45 1.25 9.51 0.017
Cardiovascular hard events
 Criteria of MetS 0.11 0.84 0.29 2.41 0.74
 Number of items for MetS 0.49 1.53 0.47 5.00 0.49
 eGFR≥60, <60 0.66 1.66 0.49 5.67 0.42
 SSS?≥9, <9 2.16 2.61 0.73 9.34 0.14
 SDS?≥2, <2 1.25 3.19 0.42 24.35 0.26
Figure 1
Kaplan-Meier survival analyses for the MetS and non-MetS groups and SSS values. Higher SSS 
has significant impact on the total event rate, but not on mortality.
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